AR070467A1 - Inhibidores de quinasa de pirrolopirazina - Google Patents
Inhibidores de quinasa de pirrolopirazinaInfo
- Publication number
- AR070467A1 AR070467A1 ARP090100620A ARP090100620A AR070467A1 AR 070467 A1 AR070467 A1 AR 070467A1 AR P090100620 A ARP090100620 A AR P090100620A AR P090100620 A ARP090100620 A AR P090100620A AR 070467 A1 AR070467 A1 AR 070467A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- lower alkyl
- haloalkyl
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000001188 haloalkyl group Chemical group 0.000 abstract 12
- 125000003545 alkoxy group Chemical group 0.000 abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Inhiben la JAK y la SYK y son utiles para el tratamiento de enfermedades inflamatorias y autoinmunes. Reivindicacion 1: Un compuesto de la formula 1 en la que: R es R1, R2, R3 o R4; R1 es alquilo inferior, alcoxi inferior, fenilo, bencilo, heteroarilo, cicloalquilo, heterocicloalquilo o cicloalquilalquilo, opcionalmente sustituido por uno o más R1a; R1a es R1b o R1c; R1b es halogeno, oxo, hidroxi o -CN; R1c es -C(=O)O(R1f), -C(=O)(CH2)m(R1e), -O(CH2)m(R1e), -S(R1f), -S(O)2(R1f) o -S(=O)(R1f), alquilo inferior, alcoxi inferior, amino, amido, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo, heterocicloalquilo, cicloalquiloxi o heterocicloalquiloxi opcionalmente sustituido por uno o más R1d; R1d es H, halogeno, hidroxi, alquilo inferior, amino, alcoxi inferior o haloalquilo inferior; R1e es H, alquilo inferior, alcoxi inferior, ciano, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo o heterocicloalquilo; R1f es H, alquilo inferior, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo o heterocicloalquilo; m es el numero 0, 1 o 2; R2 es N(R2a)2; cada R2a es con independencia H o R2b; cada R2b es con independencia alquilo inferior, fenilo, heteroarilo, cicloalquilo, heterocicloalquilo o heterocicloalquil-alquileno, opcionalmente sustituido por uno o más R2c; R2c es R2d o R2e; R2d es halogeno, oxo o hidroxi; R2e es -N(R2g)2, -C(=O)(R2g), -C(=O)O(R2g), -C(=O)N(R2g)2, -N(R2g)C(=O)(R2g), -S(=O)2(R2g), -S(O)2N(R2g)2, alquilo inferior, alcoxi inferior, haloalquilo inferior, fenilo, heteroarilo, heteroariloxi, cicloalquilo o heterocicloalquilo, opcionalmente sustituido por uno o más R2f; cada R2f es con independencia H, halogeno, alquilo inferior, alcoxi inferior, haloalquilo inferior; cada R2g es con independencia H, alquilo inferior, alcoxi inferior, haloalquilo inferior o fenilo; R3 es -C(=O)R3a; R3a es alquilo inferior, alcoxi inferior, fenilo o N(R3b)2; cada R3b es con independencia H o alquilo inferior; R4 es -O(R4a); R4a es H o R4b; R4b es alquilo inferior, fenilo, bencilo, haloalquilo inferior, cicloalquilo, heterocicloalquilo, heteroarilo, opcionalmente sustituido por uno o más R4c; R4c es halogeno, hidroxi, alquilo inferior, haloalquilo inferior o alcoxi inferior; Q4 es Q4a o Q4b; Q4a es H, hidroxi, ciano o halogeno; Q4b es alquilo inferior, alquenilo inferior, alquinilo inferior, hidroxialquilo inferior, amino o haloalquilo inferior, opcionalmente sustituido por uno o más Q4c; Q4c es Q4d o Q4e; cada Q4d es con independencia halogeno, hidroxi o ciano; cada Q4e es con independencia alquilo inferior, haloalquilo inferior, alcoxi inferior, amino, cicloalquilo, fenilo, heterocicloalquilo o heteroarilo, opcionalmente sustituido por uno o más Q4f; cada Q4f es con independencia hidroxi, halogeno, alquilo inferior, alquenilo inferior, oxo, haloalquilo inferior, alcoxi inferior, hidroxialquilo inferior o amino; con la condicion de que cuando R es R4, R4 es -O(R4a), R4a es H y Q4 es Q4a, entonces Q4a no sea H; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3103508P | 2008-02-25 | 2008-02-25 | |
| US14651409P | 2009-01-22 | 2009-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070467A1 true AR070467A1 (es) | 2010-04-07 |
Family
ID=40514045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100620A AR070467A1 (es) | 2008-02-25 | 2009-02-23 | Inhibidores de quinasa de pirrolopirazina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8119636B2 (es) |
| EP (1) | EP2247593B1 (es) |
| JP (1) | JP5284377B2 (es) |
| KR (1) | KR20100114095A (es) |
| CN (1) | CN101952296B (es) |
| AR (1) | AR070467A1 (es) |
| AT (1) | ATE519763T1 (es) |
| AU (1) | AU2009218609A1 (es) |
| BR (1) | BRPI0907928A2 (es) |
| CA (1) | CA2713718A1 (es) |
| CL (1) | CL2009000405A1 (es) |
| IL (1) | IL206818A0 (es) |
| MX (1) | MX2010009023A (es) |
| PE (1) | PE20091738A1 (es) |
| RU (1) | RU2010139284A (es) |
| TW (1) | TW200942543A (es) |
| WO (1) | WO2009106444A1 (es) |
| ZA (1) | ZA201004942B (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2247595B1 (en) * | 2008-02-25 | 2011-07-20 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| CN101952294B (zh) * | 2008-02-25 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| KR20170015566A (ko) | 2008-11-10 | 2017-02-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| EP2376485B1 (en) | 2008-12-19 | 2017-12-06 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| AU2011253021A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| KR20130066633A (ko) | 2010-05-12 | 2013-06-20 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2013529204A (ja) * | 2010-05-20 | 2013-07-18 | エフ．ホフマン−ラ ロシュ アーゲー | ピロロ［２，３−ｂ］ピラジン−７−カルボキサミド誘導体とＪＡＫ及びＳＹＫ及び阻害剤としてのそれらの使用 |
| CA2798970A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
| MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
| JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物 |
| MX2013013331A (es) | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP6096778B2 (ja) | 2011-09-01 | 2017-03-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピロロピラジンキナーゼ阻害剤 |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| KR102056586B1 (ko) | 2011-09-30 | 2019-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료 |
| EP2751099B1 (en) | 2011-09-30 | 2017-06-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| BR112014007721B1 (pt) | 2011-09-30 | 2022-11-01 | Vertex Pharmaceuticals Incorporated | Processos para preparar compostos úteis como inibidores de atr quinase |
| RU2662443C2 (ru) | 2011-11-01 | 2018-07-26 | Ф. Хоффманн-Ля Рош Аг | Имидазопиридазины |
| WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| JP2015515478A (ja) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法 |
| EP2888262B1 (en) | 2012-08-21 | 2018-12-19 | F.Hoffmann-La Roche Ag | Pyrrolo[2,3-b]pyrazines as syk inhibitors |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| BR112015012454B1 (pt) | 2012-12-07 | 2022-07-05 | Vertex Pharmaceuticals Incorporated | Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| KR20160007581A (ko) * | 2013-05-14 | 2016-01-20 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피리딘- 또는 피라진-함유 화합물 |
| ES2768678T3 (es) | 2013-12-06 | 2020-06-23 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| KR20170016498A (ko) | 2014-06-17 | 2017-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법 |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
| CR20220299A (es) | 2019-12-20 | 2022-08-05 | Pfizer | Derivados de becimidazol |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615873A (zh) | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌 |
| ES2527118T3 (es) * | 2003-12-19 | 2015-01-20 | Plexxikon Inc. | Compuestos y procedimientos de desarrollo de moduladores de Ret |
| EP1814882A1 (en) * | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
| WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| CN101952294B (zh) * | 2008-02-25 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| PL2247592T3 (pl) * | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
-
2009
- 2009-02-16 KR KR1020107018679A patent/KR20100114095A/ko not_active Ceased
- 2009-02-16 CA CA2713718A patent/CA2713718A1/en not_active Abandoned
- 2009-02-16 AU AU2009218609A patent/AU2009218609A1/en not_active Abandoned
- 2009-02-16 WO PCT/EP2009/051759 patent/WO2009106444A1/en not_active Ceased
- 2009-02-16 BR BRPI0907928-9A patent/BRPI0907928A2/pt not_active IP Right Cessation
- 2009-02-16 MX MX2010009023A patent/MX2010009023A/es not_active Application Discontinuation
- 2009-02-16 JP JP2010548070A patent/JP5284377B2/ja not_active Expired - Fee Related
- 2009-02-16 AT AT09714560T patent/ATE519763T1/de not_active IP Right Cessation
- 2009-02-16 EP EP09714560A patent/EP2247593B1/en not_active Not-in-force
- 2009-02-16 RU RU2010139284/04A patent/RU2010139284A/ru unknown
- 2009-02-16 CN CN2009801062407A patent/CN101952296B/zh not_active Expired - Fee Related
- 2009-02-20 US US12/378,837 patent/US8119636B2/en not_active Expired - Fee Related
- 2009-02-23 CL CL2009000405A patent/CL2009000405A1/es unknown
- 2009-02-23 PE PE2009000261A patent/PE20091738A1/es not_active Application Discontinuation
- 2009-02-23 AR ARP090100620A patent/AR070467A1/es unknown
- 2009-02-23 TW TW098105680A patent/TW200942543A/zh unknown
-
2010
- 2010-07-05 IL IL206818A patent/IL206818A0/en unknown
- 2010-07-13 ZA ZA2010/04942A patent/ZA201004942B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2713718A1 (en) | 2009-09-03 |
| WO2009106444A1 (en) | 2009-09-03 |
| CN101952296B (zh) | 2013-08-21 |
| ZA201004942B (en) | 2011-12-28 |
| AU2009218609A1 (en) | 2009-09-03 |
| JP5284377B2 (ja) | 2013-09-11 |
| US8119636B2 (en) | 2012-02-21 |
| PE20091738A1 (es) | 2009-11-13 |
| EP2247593A1 (en) | 2010-11-10 |
| CN101952296A (zh) | 2011-01-19 |
| JP2011513263A (ja) | 2011-04-28 |
| BRPI0907928A2 (pt) | 2015-07-28 |
| RU2010139284A (ru) | 2012-04-10 |
| CL2009000405A1 (es) | 2010-02-26 |
| EP2247593B1 (en) | 2011-08-10 |
| ATE519763T1 (de) | 2011-08-15 |
| TW200942543A (en) | 2009-10-16 |
| US20090215785A1 (en) | 2009-08-27 |
| KR20100114095A (ko) | 2010-10-22 |
| IL206818A0 (en) | 2010-12-30 |
| MX2010009023A (es) | 2010-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070467A1 (es) | Inhibidores de quinasa de pirrolopirazina | |
| AR070468A1 (es) | Pirrolopirazinas inhibidores de quinasa | |
| PE20071001A1 (es) | Derivados de 1-(azolin-2-il)-amino-1-fenil-2-hetaril-etano con actividad pesticida | |
| AR106744A2 (es) | Formas cristalinas de un compuesto de bifenilo | |
| AR036095A1 (es) | Compuestos de pirazina que actuan como ligandos del receptor de 5-ht | |
| AR080699A1 (es) | Pirrolopirazinas como inhibidores de jak y syk | |
| ES2540851T3 (es) | Compuesto de ciclopropano | |
| AR078520A1 (es) | Compuesto heterociclico y su uso para el control de una plaga de artro-podos | |
| CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
| AR085607A1 (es) | Inhibidores de la mst1 quinasa y metodos para su utilizacion | |
| DK2308419T3 (da) | Fremgangsmåde til bedømmelse af farvningstilstandene for dyresperm, som skal sorteres. | |
| CO6220855A2 (es) | Compuesto a base de 54 -fenil-6-(2,2,2-trifluoro-1-feniletoxi)pirimidina y metodos para su empleo | |
| PE20171645A1 (es) | Derivados de heterociclos biciclicos condensados sustituidos con 2-(het)arilo como agentes para combatir parasitos | |
| AR060749A1 (es) | Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas | |
| CO6321266A2 (es) | Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso | |
| BRPI0721113A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
| CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
| UY32828A (es) | Mezclas de pesticidas mesoiónicos | |
| SG167669A1 (en) | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| MX2010006313A (es) | Inhibidores de la polimerasa virica. | |
| DK3252069T3 (da) | (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme | |
| ES2778898T3 (es) | Compuestos inhibidores de la autotaxina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |